BR9910863A - Formulações farmacêuticas para igf/ igfbp - Google Patents

Formulações farmacêuticas para igf/ igfbp

Info

Publication number
BR9910863A
BR9910863A BR9910863-1A BR9910863A BR9910863A BR 9910863 A BR9910863 A BR 9910863A BR 9910863 A BR9910863 A BR 9910863A BR 9910863 A BR9910863 A BR 9910863A
Authority
BR
Brazil
Prior art keywords
igfbp
igf
pharmaceutical formulations
complex
disclosed
Prior art date
Application number
BR9910863-1A
Other languages
English (en)
Inventor
Stephen Danko
David Passmore
Yasushi Ogawa
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of BR9910863A publication Critical patent/BR9910863A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "FORMULAçõES FARMACêUTICAS PARA IGF/IGFBP". Novas formulações farmacêuticas para complexo IGF/IGFBP são descritas. Complexo IGF/IGFBP, preferivelmente complexo IGF-I/ IGFBP-3 é formulado com agentes de avolumamento e opcionalmente sais tampões, mas sem sais osmólitos adicionados. São também descritas formulações para complexo de IGF/IGFBP.
BR9910863-1A 1998-06-01 1999-05-28 Formulações farmacêuticas para igf/ igfbp BR9910863A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/089,062 US6436897B2 (en) 1998-06-01 1998-06-01 Pharmaceutical formulations for IGF/IGFBP
PCT/US1999/012173 WO1999062536A2 (en) 1998-06-01 1999-05-28 Pharmaceutical formulations for igf/igfbp

Publications (1)

Publication Number Publication Date
BR9910863A true BR9910863A (pt) 2002-06-11

Family

ID=22215473

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910863-1A BR9910863A (pt) 1998-06-01 1999-05-28 Formulações farmacêuticas para igf/ igfbp

Country Status (14)

Country Link
US (2) US6436897B2 (pt)
EP (1) EP1082133B1 (pt)
JP (1) JP2002516871A (pt)
KR (1) KR20010052500A (pt)
CN (1) CN1201816C (pt)
AT (1) ATE270898T1 (pt)
AU (1) AU4326799A (pt)
BR (1) BR9910863A (pt)
CA (1) CA2330925C (pt)
DE (1) DE69918690T2 (pt)
ES (1) ES2221456T3 (pt)
HK (1) HK1040637B (pt)
IL (1) IL139969A0 (pt)
WO (1) WO1999062536A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
ES2395035T3 (es) 2004-08-17 2013-02-07 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de la IL-1
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
ES2341270T3 (es) * 2004-12-24 2010-06-17 Insmed, Inc. Complejos rhigf-i/rhigfbp-3 purificados y procedimientos de fabricacion de los mismos.
WO2006087643A2 (en) * 2005-01-25 2006-08-24 Wyeth Research Ireland Limited Method for diafiltration
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
EP2059530B1 (en) 2006-08-31 2012-08-29 F.Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-i
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
KR101383476B1 (ko) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
EP2352514A4 (en) 2008-10-29 2012-07-25 Univ Rockefeller METHOD AND KIT FOR DISEASE TREATMENT BY ADMINISTRATION OF THE PROTEIN BINDING TO AN INSULINARY GROWTH FACTOR 2
RU2012127364A (ru) 2009-11-30 2014-01-10 Квинсленд Юниверсити Оф Текнолоджи Химеры фибронектин: фактор роста
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20190293527A1 (en) * 2013-02-04 2019-09-26 Charm Sciences, Inc. Extraction of mycotoxins
US11035764B2 (en) * 2012-02-03 2021-06-15 Charm Sciences, Inc. Extraction of mycotoxins
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US20180188139A1 (en) * 2015-06-22 2018-07-05 Dots Technology Corp. Improved assays and methods for allergen detection
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
ES2956007T3 (es) 2015-12-03 2023-12-11 Regeneron Pharma Métodos de asociación de variantes genéticas con un resultado clínico en pacientes que padecen degeneración macular asociada a la edad tratados con anti-VEGF
EP3397644A4 (en) * 2015-12-31 2018-12-19 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
JP2019534263A (ja) 2016-10-07 2019-11-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 室温で安定な凍結乾燥タンパク質
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
IL301688A (en) * 2020-10-19 2023-05-01 Oak Hill Bio Ltd The compositions are suitable for use in newborns
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
WO1995008567A1 (en) 1993-09-20 1995-03-30 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
CA2176708A1 (en) 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition

Also Published As

Publication number Publication date
ES2221456T3 (es) 2004-12-16
CA2330925A1 (en) 1999-12-09
EP1082133B1 (en) 2004-07-14
HK1040637B (zh) 2006-01-06
JP2002516871A (ja) 2002-06-11
US20030087806A1 (en) 2003-05-08
US6436897B2 (en) 2002-08-20
CA2330925C (en) 2010-02-09
DE69918690D1 (de) 2004-08-19
DE69918690T2 (de) 2005-08-18
EP1082133A2 (en) 2001-03-14
AU4326799A (en) 1999-12-20
WO1999062536A3 (en) 2000-03-30
CN1315868A (zh) 2001-10-03
WO1999062536A2 (en) 1999-12-09
US20020004478A1 (en) 2002-01-10
IL139969A0 (en) 2002-02-10
CN1201816C (zh) 2005-05-18
KR20010052500A (ko) 2001-06-25
HK1040637A1 (en) 2002-06-21
ATE270898T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
BR9910863A (pt) Formulações farmacêuticas para igf/ igfbp
ES2477568T3 (es) Uso de uridina en combinación con colina para el tratamiento de trastornos de la memoria
ES2526521T3 (es) Composiciones de antibiótico para el tratamiento del oído
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
NO20021333D0 (no) Sammensetning som innbefatter kasein- og myseprotein
EP1100522A4 (en) ADMINISTRATION OF ACTIVE SUBSTANCES BY PULMONARY TRACT
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
NO20004917L (no) Farmasøytika for avbildning av angiogene mangler
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
DK1141015T3 (da) Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
BR9906070A (pt) Benzamidas substituìdas
BR0010418B1 (pt) microorganismo de salmonella, composiÇço de vacina e uso do referido microorganismo.
BRPI9805021B1 (pt) processo para estabilizar proteìnas em um processo de congelamento e liofilização ou durante armazenagem em baixas temperaturas, forma de armazenagem e composição farmacêutica.
MY116421A (en) New formulation
PT1094802E (pt) Composicao farmaceutica para injectaveis baseada em paracetamol
SE9402880D0 (sv) New peptide derivatives
DE69815418D1 (de) Gefrier-/Kühlmittelzusammensetzung
NO952987L (no) Sårhelende blanding
ES2218796T3 (es) Uso de un compuesto peptidico para el tratamiento del lupus erimatoso sistemico.
SE9604752D0 (sv) Formulation and use
AR008236A1 (es) Forma cristalina anhidra del clorhidrato de acido r(-)-n-(4,4-di(3- metiltien-2-il)but-3-enil)-nipecotico, una composicion farmaceutica y el uso de dicha sal cristalina para la preparacion de una composicion farmaceutica
ATE121422T1 (de) Neue antikoagulatorisch wirksame peptide.
DE69822013D1 (de) Gefrier-/Kühlmittelzusammensetzung
DE69211161D1 (de) Antibiotische 7-aminonaphthazarinderivate
ES1041639Y (es) Conjunto para aplicacion de motivos graficos en el cabello.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]